Recent developments with rhodanine as a scaffold for drug discovery

Expert Opinion on Drug Discovery

Volumn 12, Issue 12, 2017, Pages 1233-1252

  Kaminskyy, Danylo ^a   Kryshchyshyn, Anna ^a   Lesyk, Roman ^a  

^a DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

Author keywords

4 thiazolidinone; Michael acceptor; PAINS; Rhodanine

Indexed keywords

RHODANINE;

ANTIBACTERIAL ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; DRUG TRANSFORMATION; HUMAN; MEDICINAL CHEMISTRY; MICHAEL ADDITION; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; CHEMISTRY; DRUG DEVELOPMENT; MOLECULARLY TARGETED THERAPY; PROCEDURES; STRUCTURE ACTIVITY RELATION;

CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; RHODANINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85033212267     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2017.1388370     Document Type: Review

References (199)

1. Ayati A, Emami S, Asadipour A, et al. Recent applications of 1,3-thiazole core structure in the identification of new lead compounds and drug discovery. Eur J Med Chem. 2015;97:699–718.
2. Kaminskyy D, Kryshchyshyn A, Lesyk R., 5-Ene-4-thiazolidinones–an efficient tool in medicinal chemistry. Eur J Med Chem. 2017;140:542-594.
3. Stojanovic M, Dzambaski Z, Bondzic B, et al. 4-Oxothiazolidines with exocyclic C=C double bond(s): synthesis structure reactions and biological activity. Curr Org Chem. 2014;18(9):1108–1148.
4. Tripathi AC, Gupta SJ, Fatima GN, et al. 4-Thiazolidinones: the advances continue…. Eur J Med Chem. 2014;72:52–57.
5. Jain VS, Vora DK, Ramaa CS. Thiazolidine-2,4-diones: progress towards multifarious applications. Bioorg Med Chem. 2013;21(7):1599–1620.
6. Jain AK, Vaidya A, Ravichandran V, et al. Recent developments and biological activities of thiazolidinone derivatives: a review. Bioorg Med Chem. 2012;20(11):3378–3395.
7. Lesyk RB, Zimenkovsky BS. 4-Thiazolidones: centenarian history current status and perspectives for modern organic and medicinal chemistry. Curr Org Chem. 2004;8(16):1547–1577.
8. Tomašić T, Peterlin Mašič L. Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation. Exp Op Drug Disc. 2012;7(7):549–560.
9. Mendgen T, Steuer C, Klein CD. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J Med Chem. 2012;55(2):743–753.
10. Lesyk RB, Zimenkovsky BS, Kaminskyy DV, et al. Thiazolidinone motif in anticancer drug discovery. Experience of DHLNMU medicinal chemistry scientific group. Biopolym. Cell. 2011;27(2):107–117.
11. Glaser J, Holzgrabe U. Focus on PAINS: false friends in the quest for selective anti-protozoal lead structures from Nature? Med Chem Comm. 2016;7(2):214–223.
12. Baell JB. Observations on screening-based research and some concerning trends in the literature. Future Med Chem. 2010;2:1529–1546.
13. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53:2719–2740.
14. Baell JB, Walters MA. Chemical con artists foil drug discovery. Nature. 2014;513:481–483.
15. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48(21):6523–6543.
16. Fortin S, Bérubé G. Advances in the development of hybrid anticancer drugs. Exp Op Drug Disc. 2013;8(8):1029–1047.
17. Mishra S, Singh P. Hybrid molecules: the privileged scaffolds for various pharmaceuticals. Eur J Med Chem. 2016;124:500–536.
18. Andleeb H, Tehseen Y, Shah SJA, et al. Identification of novel pyrazole–rhodanine hybrid scaffolds as potent inhibitors of aldose reductase: design, synthesis, biological evaluation and molecular docking analysis. RSC Adv. 2016;6(81):77688–77700.
19. Chauhan K, Sharma M, Saxena J, et al. Synthesis and biological evaluation of a new class of 4-aminoquinoline-rhodanine hybrid as potent anti-infective agents. Eur J Med Chem. 2013;62:693–704.
20. Hughes SJ, Millan DS, Kilty IC, et al. Fragment based discovery of a novel and selective PI3 kinase inhibitor. Bioorg Med Chem Lett. 2011;21(21):6586–6590.
21. Brown FC. 4-Thiazolidinones. Chem Rev. 1691;61:463–521.
22. Singh S, Parmar SS, Raman K, et al. Chemistry and biological activity of thiazolidinones. Chem Rev. 1981;81:175–203.
23. Newkome GR, Ashutosh N. 4-Thiazolidinones. Adv Heterocycl Chem. 1980;25:83–112.
24. Hajibabaei K. 2-Thioxothiazolidin-4-one (Rhodanine). Synlett. 2014;25(14):2083–2084.
25. Song MX, Zheng CJ, Deng XQ, et al. The synthesis and anti-bacterial activities of N-carboxymethyl rhodanines. Med Chem. 2014;4:441–448.
26. Yarovenko VN, Nikitina AS, Zavarzin IV, et al. A convenient synthesis of N-substituted 2-thioxo-1,3-thiazolidin-4-ones. Synthesis. 2006;8:1246–1248.
27. Radi M, Botta L, Casaluce G, et al. Practical one-pot two-step protocol for the microwave-assisted synthesis of highly functionalized rhodanine derivatives. J Comb Chem. 2009;12(1):200–205.
28. Azizi N, Hasani M, Khajeh M, et al. A straightforward and sustainable one-pot, four-component synthesis of rhodanine derivatives. Tetrahedron Lett. 2015;56(10):1189–1192.
29. Alizadeh A, Rostamnia S, Zohreh N, et al. A simple and effective approach to the synthesis of rhodanine derivatives via three-component reactions in water. Tetrahedron Lett. 2009;50:1533–1535.
30. Appalanaidu K, Dadmal T, Babu NJ, et al. An improved one-pot multicomponent strategy for the preparation of thiazoline, thiazolidinone and thiazolidinol scaffolds. RSC Adv. 2015;5:88063–88069.
31. Jacobine AM, Posner GH. Three-component, one-flask synthesis of rhodanines (thiazolidinones). J Org Chem. 2011;76(19):8121–8125.
32. Gabillet S, Lecerclé D, Loreau O, et al. Phosphine-catalyzed construction of sulfur heterocycles. Org Lett. 2007;9(20):3925–3927.
33. Shaabani A, Seyyed EH. Diversity-oriented catalyst-free synthesis of pseudopeptides containing rhodanine scaffolds via a one-pot sequential isocyanide-based six-component reactions in water using ultrasound irradiation. Ultrason Sonochem. 2018;40:84–90.
34. Halimehjani AZ, Hosseinkhany S. One-pot three-component route for the synthesis of rhodanine derivatives in water. Synthesis. 2015;47(20):3147–3152.
35. Kandeel KA, Youssef ASA. Reactions of 5-aroylmethylene-3-benzyl-4-oxo-2-thioxo-1,3-thiazolidines with nitrile oxides. Molecules. 2001;6:510–518.
36. Omar MT, El-Aasar NK, Saied KF. A one-pot synthesis of 2,3-dihydro-2-thioxothieno[2,3-d]thiazoles. Synthesis. 2001;3:413–418.
37. Lo C, Croxall WJ. Alkoxymethylenerhodanines and their reactions with rhodanines. J Am Chem Soc. 1954;76:4166–4169.
38. Yarovenko VN, Nikitina AS, Zavarzin IV, et al. Synthesis of 2-thioxo-1,3-thiazolidin-4-one derivatives. Russ Chem Bull Int Ed. 2007;56:1624–1630.
39. Atamanyuk D, Zimenkovsky B, Atamanyuk V, et al. 5-Ethoxymethylidene-4-thioxo-2-thiazolidinone as versatile building block for novel biorelevant small molecules with thiopyrano[2,3-d][1,3]thiazole core. Synth Commun. 2014;44:237–244.
40. Havrylyuk D, Zimenkovsky B, Karpenko O, et al. Synthesis of pyrazoline–thiazolidinone hybrids with trypanocidal activity. Eur J Med Chem. 2014;85:245–254.
41. Senkiv J, Finiuk N, Kaminskyy D, et al. 5-Ene-4-thiazolidinones induce apoptosis in mammalian leukemia cells. Eur J Med Chem. 2016;117:33–46.
42. Kaminskyy D, Subtel’na I, Pyrih A, et al. One-Pot Synthesis of 5-ene-4-aminothiazol-2(5H)-ones and chromeno[2,3-d]thiazol-2-ones. Synlett. 2017;28(07):811–814.
43. Kaminskyy D, Vasylenko O, Atamanyuk D, et al. Isorhodanine and thiorhodanine motifs in the synthesis of fused thiopyrano [2,3-d][1,3]thiazoles. Synlett. 2011;10:1385–1388.
44. Kaminskyy D, Khyluk D, Vasylenko O, et al. A facile synthesis and anticancer activity evaluation of spiro [thiazolidinone-isatin] conjugates. Sci Pharm. 2011;79(4):763–778.
45. Chaban TI, Ogurtsov VV, Chaban IG, et al. Synthesis and antioxidant activity evaluation of novel 5,7-dimethyl-3H-thiazolo[4,5-b]pyridines. Phosph Sulfur. 2013;188:1611–1620.
46. Kokel D, Cheung CYJ, Mills R, et al. Photochemical activation of TRPA1 channels in neurons and animals. Nat Chem Biol. 2013;9:257–263.
47. Yu F, Hu H, Gu X, et al. Asymmetric Michael addition of substituted rhodanines to α,β-unsaturated ketones catalyzed by bulky primary amines. Org Lett. 2012;14:2038–2041.
48. Popov-Pergal K, Pergal M. Study of 2-thiono group influence on some 5-(4ʹ-bromobenzylidene)-2-thiono-4-oxotetrahydro-1,3-thiazole substitution reactions. J Serb Chem Soc. 1992;57:713.
49. Nhã NT, Dương NTT, Quang TT, et al. Biological test against breast adenocarcinoma cells (MCF-7) of acylated products of 3-methyl-4-thiorhodanine. J Science Technol Develop. 2015;18:63–69.
50. Bourahla K, Derdour A, Rahmouni M, et al. A practical access to novel 2-amino-5-arylidene-1,3-thiazol-4(5H)-ones via sulfur/nitrogen displacement under solvent-free microwave irradiation. Tetrahedron Lett. 2007;48(33):5785–5789.
51. Yan M, Zhao J, Sun D, et al. Synthesis and effect on SMMC-7721 cells of new benzo[c,d]indole rhodanine complex merocyanines as PDT photosensitizers. Tetrahedron. 2017;73(24):3355–3362.
52. Insuasty B, Insuasty A, Tigreros A, et al. Synthesis and antifungal evaluation of novel dicyanoderivatives of rhodanine. J Heterocycl Chem. 2011;48(2):347–350.
53. Insuasty A, Ramírez J, Raimondi M, et al. Synthesis, antifungal and antitumor activity of novel (Z)-5-hetarylmethylidene-1,3-thiazol-4-ones and (Z)-5-ethylidene-1,3-thiazol-4-ones. Molecules. 2013;18(5):5482–5497.
54. Baharfar R, Shariati N. An efficient one-pot synthesis of novel isatin-based 2-amino thiazol-4-one conjugates using MgO nanoparticles in aqueous media. Comptes Rendus Chim. 2014;17:413–419.
55. Peng ZH, Zhou XF, Carroll S, et al. Structure of rhodanine dyes, spectroscopy and performance in photographic emulsions. J Mater Chem. 1996;6:1325–1333.
56. Takasu K, Inoue H, Kim H-S, et al. Rhodacyanine dyes as antimalarials 1. Preliminary evaluation of their activity and toxicity. J Med Chem. 2002;45:995–998.
57. Pudhom K, Kasai K, Terauchi H, et al. Synthesis of three classes of rhodacyanine dyes and evaluation of their in vitro and in vivo antimalarial activity. Bioorg Med Chem. 2006;14(24):8550–8563.
58. Gerencsér J, Dormán G, Darvas F. Meldrum’s acid in multicomponent reactions: applications to combinatorial and diversity‐oriented synthesis. QSAR Comb Science. 2006;25:439–448.
59. Yadav LDS, Rai VK. Chemoselective annulation of 1,3-dithiin, -thiazine and -oxathiin rings on thiazoles using a green protocol. Tetrahedron. 2006;62:8029–8034.
60. Hiroshi N. Studies on fungicides. XXII. Reaction of dimethyl acetylenedicarboxylate with dithiocarbamates, thiolcarbamates, thiosemicarbazides and thiosemicarbazones. Chem Pharm Bull. 1973;21:279–286.
61. Yadav LDS, Singh A. Multi-component synthesis of pyran-annulated thiazoles under solvent-free microwave irradiation. Synthesis. 2003;15:2395–2399.
62. Yarovenko VN, Nikitina AS, Zavarzin IV, et al. Synthesis of fused heterocyclic compounds on the basis of 2-thioxo-1,3-thiazolidin-4-ones. Rus J Org Chem. 2007;43:1364–1370.
63. El-Shafei AK, El-Sayed AM, Sultan A, et al. Application of phase‐transfer catalysis in reactions with some rhodanine derivatives. Gazz Chim Ital. 1990;120:197–203.
64. Wu W, Huang H, Yuan X, et al. Asymmetric construction of spirocyclohexanone rhodanines catalyzed by simple diamine derived from chiral tert-leucine. Chem Commun. 2012;48:9180–9182.
65. Matiychuk VS, Lesyk RB, Obushak MD, et al. A new domino-Knoevenagel-hetero-Diels-Alder reaction. Tetrahedron Lett. 2008;49:4648–4651.
66. Majumdar KC, Taher A, Nandi RK. Synthesis of heterocycles by domino-Knoevenagel–hetero-Diels-Alder reactions. Tetrahedron. 2012;68:5693–5718.
67. Zhu K, Huang H, Wu W, et al. Aminocatalyzed asymmetric Diels–Alder reaction of 2,4-dienals and rhodanine/hydantoin derivatives. Chem Commun. 2013;49:2157–2159.
68. Liu H, Zou Y, Hu Y, et al. An efficient one‐pot synthesis of dispiropyrrolidine derivatives through 1,3‐dipolar cycloaddition reactions under ultrasound irradiation. J Heterocycl Chem. 2011;48:877–881.
69. Dobrina VA, Ioffe DV. Synthesis of α-cyclopentylmandelic acid. Pharm Chem J. 1978;11:817–818.
70. Kaminskyy D, Khyluk D, Vasylenko O, et al. An efficient method for the transformation of 5-ylidenerhodanines into 2,3,5-trisubstituted-4-thiazolidinones. Tetrahedron Lett. 2012;53:557–559.
71. Brem J, Van Berkel SS, Aik W, et al. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition. Nature Chem. 2014;6(12):1084–1090.
72. Kottakota SK, Benton M, Evangelopoulos D, et al. Versatile routes to marine sponge metabolites through benzylidene rhodanines. Organic Lett. 2012;14(24):6310–6313.
73. Eiserband G, Otteneder M, Tang W. Synthesis of N-acetyl-S-(3-coumarinyl)-cysteine and HPLC analisis of urinary coumarine metabolites. Toxicol. 2003;109:249–258.
74. Xing QY, Wang WJ, He DY. 3-Thiolcoumarin and its derivatives. Acta Chim Sint. 1987;45:344–353.
75. Pardasani RT, Pardasani P, Sherry D, et al. Synthetic and antibacterial studies of rhodanine derivatives with indole-2,3-diones. Ind J Chem. 2001;40B:1275–1278.
76. Dijksman DJ, Newbold GT. 1:2-Dihydro-2-thianaphthalenederivatives. Part I. Preparation and reactions of 1:2-dihydro-1-keto-2-thianaphthalenes. J Chem Soc. 1951;0:1213–1218.
77. Pokhodylo NT, Matiychuk VS, Obushak MD. A convenient method for the synthesis of thiopyrano[4,3-c]quinoline, a new heterocyclic system. Chem Heterocyc Compd. 2009;45:121–122.
78. Kaminskyy D, Kryshchyshyn A, Nektegayev I, et al. Isothiocoumarin-3-carboxylic acid derivatives: synthesis, anticancer and antitrypanosomal activity evaluation. Eur J Med Chem. 2014;75:57–66.
79. Mori M, Moraca F, Deodato D, et al. Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor. Bioorg Med Chem Lett. 2014;24(11):2508–2511.
80. Tejchman W, Korona-Glowniak I, Malm A, et al. Antibacterial properties of 5-substituted derivatives of rhodanine-3-carboxyalkyl acids. Med Chem Res. 2017;26(6):1316–1324.
81. Kaminskyy DV. Screening of the antiviral activity in the range of С5 and N3 substituted 4-thiazolidinone derivatives. J Pharm Ogr Chem. 2015;13(2):64–69.
82. Kaminskyy DV, Lesyk RB. Structure–anticancer activity relationships among 4-azolidinone-3-carboxylic acids derivatives. Biopolym Cell. 2010;26(2):136–145.
83. Zhang Y, Wang S, Wu S, et al. Facile construction of structurally diverse thiazolidinedione-derived compounds via divergent stereoselective cascade organocatalysis and their biological exploratory studies. ACS Comb Sci. 2013;15:298–308.
84. Oh S, Park SB. A design strategy for drug-like polyheterocycles with privileged substructures for discovery of specific small-molecule modulators. Chem Commun. 2011;47:12754–12761.
85. Ramirez MA, Borja NL. Epalrestat: an aldose reductase inhibitor of the treatment of diabetic neuropathy. Pharmacotherap. 2008;28:646–655.
86. Verma A, Saraf SK. 4-Thiazolidinone–a biologically active scaffold. Eur J Med Chem. 2008;43:897–905.
87. Bhatti RS, Shah S, Krishan P, et al. Recent pharmacological developments on rhodanines and 2, 4-thiazolidinediones. Int J Med Chem. 2013;2013:793260.
88. Sawaguchi Y, Yamazaki R, Nishiyama Y, et al. Rational design of a potent Pan-Pim kinases inhibitor with a rhodanine–benzoimidazole structure. Anticancer Res. 2017;37(8):4051–4057.
89. Bataille CJ, Brennan MB, Byrne S, et al. Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family. Bioorg Med Chem. 2017;25(9):2657–2665.
90. Vatolin S, Phillips JG, Jha BK, et al. Novel protein disulfide isomerase inhibitor with anticancer activity in multiple myeloma. Cancer Res. 2016;76(11):3340–3350.
91. Huang MJ, Cheng YC, Liu CR, et al. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol. 2006;34(11):1480–1489.
92. Degterev A, Lugovskoy A, Cardone M, et al. Identification of small-molecule inhibitors of the interaction between the BH3 domain and Bcl-xL. Nat Cell Biol. 2001;3:173–182.
93. Cutshall NS, O’Day C, Prezhdo M. Rhodanine derivatives as inhibitors of JSP-1. Bioorg Med Chem Lett. 2005;15:3374–3379.
94. Grant EB, Guiadeen D, Baum EZ, et al. The synthesis and SAR of rhodanines as novel class C-lactamase inhibitors. Bioorg Med Chem Lett. 2000;10:2179–2182.
95. Suree N, Yi SW, Thieu W, et al. Discovery and structure-activity relationship analysis of Staphylococcus Aureus sortase A inhibitors. Bioorg Med Chem. 2009;17:7174–7185.
96. Howard MH, Cenizal T, Gutteridge S. A novel class of inhibitors of peptide deformylase discovered through high-throughput screening and virtual ligand screening. J Med Chem. 2004;47:6669–6672.
97. Carlson EE, May JF, Kiessling LL. Chemical probes of UDP-galactopyranose mutase. Chem Biol. 2006;13(8):825–837.
98. Sim MM, Ng SB, Buss AD, et al. Benzylidene rhodanines as novel inhibitors of UDP-N-acetylmuramate/L-alanine ligase. Bioorg Med Chem Lett. 2002;12:697–699.
99. Zidar N, Tomašić T, Šink R, et al. Discovery of novel 5-benzylidenerhodanine and 5-benzylidenethiazolidine-2,4-dione inhibitors of MurD ligase. J Med Chem. 2010;53(18):6584–6594.
100. Smith TK, Young BL, Denton H, et al. First small molecular inhibitors of t. brucei dolicholphosphate mannose synthase (DPMS), a validated drug target in african sleeping sickness. Bioorg Med Chem Lett. 2009;19:1749–1752.
101. El-Miligy MM, Hazzaa AA, El-Messmary H, et al. New hybrid molecules combining benzothiophene or benzofuran with rhodanine as dual COX-1/2 and 5-LOX inhibitors: synthesis, biological evaluation and docking study. Bioorg Chem. 2017;72:102–115.
102. Proschak E, Zettl H, Tanrikulu Y, et al. From molecular shape to potent bioactive agents I: bioisosteric replacement of molecular fragments. Chem Med Chem. 2009;4:41–44.
103. Choi J, Ko Y, Lee HS, et al. Identification of (b-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor γ activity. Eur J Med Chem. 2010;45:193–202.
104. Wang GC, Peng YP, Xie ZZ, et al. Synthesis, α-glucosidase inhibition and molecular docking studies of novel thiazolidine-2,4-dione or rhodanine derivatives. Med Chem Comm. 2017;8(7):1477–1484.
105. Ono M, Hayashi S, Matsumura K, et al. Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer’s brains. ACS Neurosci. 2011;2(5):269–275.
106. Powers JP, Piper DE, Li Y, et al. SAR and mode of action of novel nonnucleoside inhibitors of hepatitis C NS5B RNA polymerase. J Med Chem. 2006;49:1034–1046.
107. Lee G, Piper DE, Wang Z, et al. Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. J Mol Biol. 2006;357:1051–1057.
108. Talele TT, Arora P, Kulkarni SS, et al. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem. 2010;18:4630–4638.
109. Sing WT, Lee CL, Yeo SL, et al. Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor. Biorg Med Chem Lett. 2001;11:91–94.
110. Maga F, Falchi A, Garbelli A, et al. Pharmacophore modeling and molecular docking led to the discovery of inhibitors of human immunodeficiency virus-1 replication targeting the human cellular aspartic acid-glutamic acid-alanine-aspartic acid box polypeptide 3. J Med Chem. 2008;51:6635–6638.
111. Dayam R, Sanchez T, Clement O, et al. β-Diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. J Med Chem. 2005;48:111–120.
112. Volynets G, Bdzhola VG, Golub AG, et al. Rational design of apoptosis signal-regulating kinase 1 inhibitors: discovering novel structural scaffold. Eur J Med Chem. 2013;61:104–115.
113. Kim HJ, Choo H, Cho YS, et al. Novel GSK-3β inhibitors from sequential virtual screening. Bioorg Med Chem. 2008;16:636–643.
114. Szewczuk LM, Saldanha SA, Ganguly S, et al. De novo discovery of serotonin N-acetyltransferase inhibitors. J Med Chem. 2007;50:5330–5338.
115. Furdas SD, Shekfeh S, Kannan S, et al. Rhodanine carboxylic acids as novel inhibitors of histone acetyltransferases. Med Chem Comm. 2012;3:305–311.
116. Kaminskyy DV, Roman OM, Atamanyuk DV, et al. 5-Ylidene-2-thioxo-4-thiazolidinone-3-succinic acids and their derivatives: synthesis, anticancer activity, QSAR-analysis. J Org Pharm Chem. 2006;4:41–48. Ukrainian.
117. Havrylyuk D, Zimenkovsky B, Vasylenko O, et al. Synthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activity. J Med Chem. 2012;55:8630–8641.
118. Kaminskyy D, Zimenkovsky B, Lesyk R. Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives. Eur J Med Chem. 2009;44:3627–3636.
119. Havrylyuk D, Mosula L, Zimenkovsky B, et al. Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety. Eur J Med Chem. 2010;45:5012–5021.
120. Kavitha CV, Chandrappa S, Narasimhamurthy KH, et al. Synthesis and evaluation of 5-((5-(4-methoxyphenyl)furan-2-yl)methylene)thiazolidine-2,4-diones as a new class of cytotoxicagents for leukemia treatment. Asian J Biochem Pharm Res. 2014;4:309–323.
121. Kumar KSS, Hanumappa A, Hegde M, et al. Synthesis and antiproliferative effect of novel 4-thiazolidinone-, pyridine- and piperazine-based conjugates on human leukemic cells. Eur J Med Chem. 2014;81:341–349.
122. Moorthy BT, Ravi S, Srivastava M, et al. Novel rhodanine derivatives induce growth inhibition followed by apoptosis. Bioorg Med Chem Lett. 2010;20:6297–6301.
123. Dago CD, Ambeu CNT, Coulibaly WK, et al. Investigation on the synthesis of new 3-[4-(arylalkoxy)phenylethyl]-2-thioxo-1,3-thiazolidin-4-ones and their biological evaluation against cancer cells. Chem Heterocycl Comp. 2017;53(3):341–349.
124. Stawoska I, Tejchman W, Mazuryk O, et al. Spectral characteristic and preliminary anticancer activity in vitro of selected rhodanine‐3‐carboxylic acids derivatives. J Heterocycl Chem. 2017. DOI:10.1002/jhet.2897
125. Lin CP, Liu JD, Chow JM, et al. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anti-Cancer Drugs. 2007;18(2):161–170.
126. Onen-Bayram FE, Durmaz I, Scherman D, et al. A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells. Bioorg Med Chem. 2012;20:5094–5102.
127. Gududuru V, Hurh E, Dalton JT, et al. Discovery of 2-arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer. J Med Chem. 2005;48:2584–2588.
128. Li W, Wang Z, Gududuru V, et al. Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. Anticancer Res. 2007;27:883–888.
129. Chumak VV, Мr F, Panchuk RR, et al. Study of antineoplastic action of novel isomeric derivatives of 4-thiazolidinone. Ukr Biochem J. 2014;86:96–105.
130. Asati V, Mahapatra DK, Bharti SK. Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: potential anticancer agents. Eur J Med Chem. 2014;87:814–833.
131. Joshi H, Pal T, Ramaa CS. A new dawn for the use of thiazolidinediones in cancer therapy. Exp Op Drug Disc. 2014;23(4):501–510.
132. Chou FS, Wang PS, Kulp S, et al. Effects of thiazolidinediones on differentiation, proliferation, and apoptosis. Mol Cancer Res. 2007;5:523–530.
133. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10:389–399.
134. Teraishi F, Wu SH, Sasaki J, et al. P-Glycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT 5-(4-methylphenyl)methylene-2-(phenylamino)-4(5H)-thiazolone. J Pharmacol Exper Ther. 2005;314:355–362.
135. Miyata Y, Li X, Lee HF, et al. Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor mkt-077, which reduces tau levels. ACS Neurosci. 2013;4:930–939.
136. Rousaki A, Miyata Y, Jinwal CA, et al. Allosteric drugs: the interaction of antitumor compound MKT-077 with human Hsp70 chaperones. J Mol Biol. 2011;411(3):614–632.
137. Tomasic T, Masic L. Rhodanine as a privileged scaffold in drug discovery. Curr Med Chem. 2009;16(13):1596–1629.
138. Xu LL, Zheng CJ, Sun LP, et al. Synthesis of novel 1,3-diaryl pyrazole derivatives bearing rhodanine-3-fatty acid moieties as potential antibacterial agents. Eur J Med Chem. 2012;48:174–178.
139. Jin X, Zheng CJ, Song MX, et al. Synthesis and antimicrobial evaluation ofL-phenylalanine-derived C5-substituted rhodanine andchalcone derivatives containing thiobarbituric acid or 2-thioxo-4-thiazolidinone. Eur J Med Chem. 2012;56:203–209.
140. Ge X, Wakim B, Sem DS. Chemical proteomics-based drug design: target and antitarget fishing with a catechol−rhodanine privileged scaffold for NAD(P)(H) binding proteins. J Med Chem. 2008;51(15):4571–4580.
141. Song MX, Li SH, Peng JY, et al. Synthesis and bioactivity evaluation of N-arylsulfonylindole analogs bearing a rhodanine moiety as antibacterial agents. Molecules. 2017;22(6):970.
142. Krátký M, Vinšová J, Stolaříková J. Antimicrobial activity of rhodanine-3-acetic acid derivatives. Bioorg Med Chem. 2017;25(6):1839–1845.
143. Subhedar DD, Shaikh MH, Shingate BB, et al. Quinolidene-rhodanine conjugates: facile synthesis and biological evaluation. Eur J Med Chem. 2017;125:385–399.
144. Orchard MG, Neuss JC, Galley CMS, et al. Rhodanine-3-acetic acid derivatives as inhibitors of fungal protein mannosyl transferase 1 (PMT1). Bioorg Med Chem Lett. 2004;14:3975–3978.
145. Chen ZH, Zheng CJ, Sun LP, et al. Synthesis of new chalcone derivatives containing a rhodanine-3-acetic acid moiety with potential anti-bacterial activity. Eur J Med Chem. 2010;45(12):5739–5743.
146. Zheng CJ, Song MX, Sun LP, et al. Synthesis and biological evaluation of 5-aryloxypyrazole derivatives bearing a rhodanine-3-aromatic acid as potential antimicrobial agents. Bioorg Med Chem Lett. 2012;22(23):7024–7028.
147. Song Y, Connor DT, Doubleday R, et al. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. J Med Chem. 1999;42:1151–1160.
148. Bulic B, Pickhardt M, Khlistunova I, et al. Rhodanine‐based Tau aggregation inhibitors in cell models of tauopathy. Angew Chem Int Ed. 2007;46(48):9215–9219.
149. Kryshchyshyn A, Kaminskyy D, Grellier P, et al. Trends in research of antitrypanosomal agents among synthetic heterocycles. Eur J Med Chem. 2014;85:51–64.
150. Kaminskyy D, den Hartog GJ, Wojtyra M, et al. Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones. Eur J Med Chem. 2016;112:180–195.
151. Yelisyeyeva OP, Semen KO, Ostrovska GV, et al. The effect of Amaranth oil on monolayers of artificial lipids and hepatocyte plasma membranes with adrenalin-induced stress. Food Chem. 2014;147:152–159.
152. Hossain SU, Bhattacharya S. Synthesis of O-prenylated and O-geranylated derivatives of 5-benzylidene-2,4-thiazolidinediones and evaluation of their free radical scavenging activity as well as effect on some phase ii antioxidant/detoxifying enzymes. Bioorg Med Chem Lett. 2007;17:1149–1154.
153. Geronikaki AA, Pitta E, Liaras KS. Thiazoles and thiazolidinones as antioxidants. Curr Med Chem. 2013;20:4460–4480.
154. Aly AA, Brown AB, Abdel‐Aziz M, et al. An efficient synthesis of thiazolidine-4-ones with antitumor and antioxidant activities. J Heterocycl Chem. 2012;49:726–731.
155. Botta L, Maccari G, Calandro P, et al. One drug for two targets: biological evaluation of antiretroviral agents endowed with antiproliferative activity. Bioorg Med Chem Lett. 2017;27(11):2502–2505.
156. Saha S, New LS, Ho HK, et al. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicol Lett. 2010;192:141.
157. Tang SQ, Lee YYI, Packiaraj DS, et al. Systematic evaluation of the metabolism and toxicity of thiazolidinone and imidazolidinone heterocycles. Chem Res Toxicol. 2015;28(10):2019–2033.
158. Zeiger E, Anderson B, Haworth S, et al. Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals. Environm Mol Mutagen. 1987;9:61–109.
159. Morishima Y, Isono M, Iton Y, et al. Synthesys of some polimeric dyes and sensitized photoelectrode proceses by the polymer-coated electrodes. Chem Lett. 1981;10(8):1149–1152.
160. Rekai ED, Baudin JB, Jullien L, et al. A hyperpolar, multichromophoric cyclodextrin derivative: synthesis, and linear and nonlinear optical properties. Chem Eur J. 2001;20(7):4395–4402.
161. Sun K, Xiao Z, Lu S, et al. A molecular nematic liquid crystalline material for high-performance organic photovoltaics. Nature Comm. 2015;6:6013.
162. Yang Z, Kuang W, Weng P, et al. Graphene oxide/rhodanine redox chemistry and its application in designing high-performance elastomer/graphene composites. RSC Adv. 2015;5(103):84398–84405.
163. Moribe S, Kato N, Higuchi K, et al. Control of interfacial charge-transfer interaction of dye and p-CuI in solid-state dye-sensitized solar cells. Appl Phys Express. 2017;10(4):042301.
164. Wan Z, Jia C, Wang Y, et al. A strategy to boost the efficiency of rhodanine electron acceptor for organic dye: from nonconjugation to conjugation. ACS Appl Mat Interfac. 2017;9(30):25225–25231.
165. Nelson KM, Dahlin JL, Bisson J, et al. The essential medicinal chemistry of curcumin: miniperspective. J Med Chem. 2017;60(5):1620–1637.
166. Ahn BZ, Sok DE. Michael acceptors as a tool for anticancer drug design. Curr Pharm Design. 1996;2:247–262.
167. Schwöbel JA, Wondrousch D, Koleva YK, et al. Prediction of Michael-type acceptor reactivity toward glutathione. Chem Res Toxicol. 2010;23(10):1576–1585.
168. Mulliner D, Wondrousch D, Schüürmann G. Predicting Michael-acceptor reactivity and toxicity through quantum chemical transition-state calculations. Org Biomol Chem. 2011;9(24):8400–8412.
169. Schultz TW, Yarbrough JW, Hunter RS, et al. Verification of the structural alerts for Michael acceptors. Chem Res Toxicol. 2007;20(9):1359–1363.
170. Pinson JA, Schmidt-Kittler O, Frazzetto M, et al. Synthesis and pharmacological evaluation of 4-iminothiazolidinones for inhibition of PI3 kinase. Aust J Chem. 2012;65:1396–1404.
171. Zhou H, Wu S, Zhai S, et al. Design, synthesis, cytoselective toxicity, structure activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem. 2008;51:1242–1251.
172. Smelcerovic Z, Veljkovic A, Kocic G, et al. Xanthine oxidase inhibitory properties and anti-inflammatory activity of 2-amino-5-alkylidene-thiazol-4-ones. Chem Biol Interact. 2015;229:73–81.
173. Jackson PA, Widen JC, Harki DA, et al. Covalent modifiers: a chemical perspective on the reactivity of α,β-unsaturated carbonyls with thiols via hetero-Michael addition reactions. J Med Chem. 2016;60(3):839–885.
174. Avonto C, Taglialatela‐Scafati O, Pollastro F, et al. An NMR spectroscopic method to identify and classify thiol‐trapping agents: revival of Michael acceptors for drug discovery? Angew Chem Int Ed. 2011;50(2):467–471.
175. Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. Proc Nat Acad Sci. 2003;100:7977–7982.
176. Monzon JG, Dancey J. Combination agents versus multitargeted agents–pro and cons. In: Morphy JR, Harris CJ, editors. Designing multi-target drugs. Cambridge: RSC Publishing; 2012. p. 155–181.
177. Kupchan SM, Fessler DC, Eakin MA, et al. Reactions of alpha methylene lactone tumor inhibitors with model biological nucleophiles. Science. 1970;168(3929):376–378.
178. Shi B, Greaney MF. Reversible Michael addition of thiols as a new tool for dynamic combinatorial chemistry. Chem Commun. 2005;7:886–888.
179. Nair DP, Podgórski M, Chatani S, et al. The thiol-Michael addition click reaction: a powerful and widely used tool in materials chemistry. Chem Mater. 2014;26(1):724–744.
180. Riel-Mehan MM, Shokat KM. A crosslinker based on a tethered electrophile for mapping kinase-substrate networks. Chem Biol. 2014;21(5):585–590.
181. Rodrigues T, Reker D, Schneider P, et al. Counting on natural products for drug design. Nature Chem. 2016;8(6):531–541.
182. Bauer RA. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today. 2015;20(9):1061–1073.
183. Kim K, Kim SJ, Han YT, et al. Identification of small molecule inhibitors of the STAT3 signaling pathway: insights into their structural features and mode of action. Bioorg Med Chem Lett. 2015;25(22):5444–5448.
184. Gersch M, Kreuzer J, Sieber SA. Electrophilic natural products and their biological targets. Nat Prod Rep. 2012;29(6):659–682.
185. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exper Therap. 2012;343(2):342–350.
186. Mohell N, Alfredsson J, et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 2015;6(6):1794.
187. Dinkova-Kostova AT, Massiah MA, Bozak RE, et al. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Nat Acad Sci. 2001;98(6):3404–3409.
188. Kumar H, Kim IS, More SV, et al. Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases. Nat Prod Rep. 2014;31(1):109–139.
189. Syu JP, Chi JT, Kung HN. Chapter 5. Nrf2 Contributes to the poor prognosis and chemoresistance. In: Morales JA, Morales-Gonzales A, Mandrigal-Santillan EO, editors. A master regulator of oxidative stress-the transcription factor Nrf2. InTech; 2016. doi:10.5772/65105
190. Forman HJ, Davies KJA, Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radical Biol Med. 2014;6:24–35.
191. Egea J, Fabregat I, Frapart YM, et al. European contribution to the study of ROS: a summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biol. 2017;13:94–162.
192. Hildyard JCW, Ämmälä C, Dukes ID, et al. Identification and characterisation of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrier. Biochim Biophys Acta Bioenerg. 2005;1707:221–230.
193. Perdih A, Hrast M, Pureber K, et al. Furan-based benzene mono-and dicarboxylic acid derivatives as multiple inhibitors of the bacterial Mur ligases (MurC–MurF): experimental and computational characterization. J Comput Aid Mol Des. 2015;29(6):541–560.
194. Perdih A, Hrast M, Barreteau H, et al. Benzene-1, 3-dicarboxylic acid 2, 5-dimethylpyrrole derivatives as multiple inhibitors of bacterial Mur ligases (MurC–MurF). Bioorg Med Chem. 2014;22(15):4124–4134.
195. Dahlin JL, Nissink JWM, Strasser JM, et al. PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J Med Chem. 2015;58(5):2091–2113.
196. Song ZJ, Ng MY, Lee ZW, et al. Hydrogen sulfide donors in research and drug development. Med Chem Comm. 2014;5(5):557–570.
197. 2S) releasing agents: chemistry and biological applications. Chem Commun. 2014;50(80):11788–11805.
198. Wallace JL, Wang R. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Drug Discov. 2015;14(5):329.
199. Nottbohm AC, Hergenrother PJ. Phosphate mimics: cyclic compounds. In: Wiley encyclopedia of chemical biology. Begley TP (Chief advisor). 2008. John Wiley & Sons Inc;1943-57.